Close
CDMO Safety Testing 2026
Novotech

BioLife Solutions to build second GMP production facility

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

Cell and Gene Therapy Manufacturing Entering GMP Era

The rapid and profound maturation of the global biopharmaceutical sector is being clearly marked by cell and gene therapy manufacturing entering GMP era. This critical transition involves the large-scale implementation of rigorous and uncompromising Good Manufacturing Practice standards to ensure that these complex, "living" treatments are produced with a level of consistent quality and safety that meets international requirements. By adopting highly automated systems, closed-loop processing, and robust, data-driven regulatory frameworks, the industry is successfully overcoming the historical hurdles of scalability and biological variability, paving the way for these advanced therapies to reach much broader patient populations across the globe.

How to Source the Best Color Spectrophotometers and Colorimeters for Pharma QC

Color consistency is critical in pharmaceutical quality control (QC)....

Shilpa Medicare, NXI Therapeutics AG Enters Partnership

A long-term development and commercial manufacturing agreement has been...
- Advertisement -

BioLife Solutions has executed an amendment to its current commercial lease to double the area of its existing facilities.

The additional space will be used to the build a second GMP manufacturing clean room suite and space for team members.ย BioLife Solutions chief executive officer Mike Rice said they are pleased to see demand for HypoThermosol and CryoStor continuing to increase.

“This growth, along with a new contract manufacturing customer we acquired late in 2011, will enable BioLife to create up to 10 additional jobs in manufacturing, quality assurance, sales, and marketing,” Rice added.ย BioLife Solutions chief financial officer Daphne Taylor said they look forward to increasing the company’s manufacturing capacity and the size of the team to meet the growing demand for its products and services.

The company said shipments to BioLife’s new contract manufacturing customer are expected to begin in the second quarter of this year.ย BioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells and tissues.

World Pharma Today brings together the global pharmaceutical industry โ€” from R&D leaders and regulatory affairs professionals to manufacturers and distribution executives โ€” through trusted editorial, market intelligence, and digital engagement.

Our 2026 Media Pack offers integrated solutions to reach your audience:

  • Magazine & Digital Editions Showcase your brand within premium pharmaceutical industry coverage read by executives and decision - makers worldwide.
  • Industry Insights & Reports Align with data - driven analysis, trend reports, and regional roundups across the global pharmaceutical and life sciences value chain.
  • Brand Authority & Credibility Position your company as a thought leader through expert commentary, interviews, and special features.

Latest stories

Related stories

Cell and Gene Therapy Manufacturing Entering GMP Era

The rapid and profound maturation of the global biopharmaceutical sector is being clearly marked by cell and gene therapy manufacturing entering GMP era. This critical transition involves the large-scale implementation of rigorous and uncompromising Good Manufacturing Practice standards to ensure that these complex, "living" treatments are produced with a level of consistent quality and safety that meets international requirements. By adopting highly automated systems, closed-loop processing, and robust, data-driven regulatory frameworks, the industry is successfully overcoming the historical hurdles of scalability and biological variability, paving the way for these advanced therapies to reach much broader patient populations across the globe.

How to Source the Best Color Spectrophotometers and Colorimeters for Pharma QC

Color consistency is critical in pharmaceutical quality control (QC)....

Shilpa Medicare, NXI Therapeutics AG Enters Partnership

A long-term development and commercial manufacturing agreement has been...

Novartis Expands Radioligand Therapy Manufacturing in US

Swiss pharmaceutical company Novartis has started construction of a...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป